Premixed vs Sequential Injections of Lidocaine and Bupivacaine for Supraclavicular Brachial Plexus Block in Patients Undergoing Arteriovenous Fistula Creation

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 24, 2024

Primary Completion Date

March 16, 2025

Study Completion Date

March 16, 2025

Conditions
PremixedSequentialLidocaineBupivacaineSupraclavicular Brachial Plexus BlockArteriovenous Fistula
Interventions
DRUG

Lidocaine 2% then bupivacaine 0.5%

Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.

DRUG

Lidocaine 2% and bupivacaine 0.5%

Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.

Trial Locations (1)

31527

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06570096 - Premixed vs Sequential Injections of Lidocaine and Bupivacaine for Supraclavicular Brachial Plexus Block in Patients Undergoing Arteriovenous Fistula Creation | Biotech Hunter | Biotech Hunter